(BusinessWire) January 26, 2011 – Altra Investments Inc. (Altra) and The Rohatyn Group (TRG) announced the sale of their controlling interest in Corporación Infarmasa S.A. (Infarmasa) to Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.
Infarmasa, one of the largest independently-owned pharmaceutical companies in Peru, manufactures and commercializes branded and unbranded generic products and currently holds a preeminent position in its domestic market.
Since acquiring control of Infarmasa in August 2007, Altra and TRG have actively supported its growth strategy, which included expanding its product mix, launching new business lines, developing new export markets, optimizing its capital structure and strengthening its corporate governance.
Mauricio Camargo of Altra commented, “We congratulate Infarmasa and its management for positioning the company to take advantage of this outstanding opportunity.”
Roberto Chute of TRG added, “Becoming part of the Teva Group, should enable Infarmasa to expand its leading position in Perú and throughout the region.”
Both Messrs. Camargo and Chute served on the company’s board of directors prior to the sale.
Teva, headquartered in Israel, specializes in the development, production and marketing of generic and proprietary branded pharmaceuticals products. The company has direct presence in over 50 countries, more than 40,000 employees and revenues of $13.9 billion in 2009.
Credit Suisse acted as the financial advisor to Altra Investments and The Rohatyn Group.
About ALTRA Investments
Altra is a private equity firm founded in early 2005 with an investment focus in mid market companies in the Andean Region and Central America, with a special emphasis in Colombia and Peru. The firm is led by Mauricio Camargo, Dario Duran and Jorge Kuryla, out of offices in Bogota and Lima. Since inception, Altra has mobilized approximately $ 270 million of investment capital and currently operates seven investments with direct operations in Colombia, Peru, Guatemala, El Salvador, Nicaragua, Argentina, and Spain.
About The Rohatyn Group
The Rohatyn Group (TRG) is a leading asset management firm solely focused on investing in emerging markets. TRG’s management team is composed of senior professionals with extensive experience in the emerging and global markets. The firm currently manages $3 billion in products across asset classes, in both liquid and illiquid markets and across investment approaches including private equity. TRG’s investment professionals and robust risk management, research, legal, client service and information technology teams are located in offices in New York, London, Hong Kong, Singapore, Johannesburg, Montevideo, Buenos Aires, Lima and Sao Paulo.